Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma

Carina Hage, Sabine Hoves, Léanne Strauss, Stefan Bissinger, Ylva Prinz, Thomas Pöschinger, Fabian Kiessling, Carola H. Ries – 19 April 2019 – Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). We report that sorafenib also acts through direct immune modulation, indispensable for its antitumor activity.

Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes

Llilda Barata, Mary F. Feitosa, Lawrence F. Bielak, Brian Halligan, Abigail S. Baldridge, Xiuqing Guo, Laura M. Yerges‐Armstrong, Albert V. Smith, Jie Yao, Nicholette D. Palmer, Lisa B. VanWagner, J. Jeffrey Carr, Yii‐Der I. Chen, Matthew Allison, Matthew J. Budoff, Samuel K. Handelman, Sharon L.R. Kardia, Thomas H. Mosley, Kathleen Ryan, Tamara B. Harris, Lenore J. Launer, Vilmundur Gudnason, Jerome I. Rotter, Myriam Fornage, Laura J. Rasmussen‐Torvik, Ingrid B. Borecki, Jeffrey R. O’Connell, Patricia A. Peyser, Elizabeth K. Speliotes, Michael A.

Nocturnal Hypoxia Activation of the Hedgehog Signaling Pathway Affects Pediatric Nonalcoholic Fatty Liver Disease Severity

Shikha S. Sundaram, Marzena Swiderska‐Syn, Ronald J. Sokol, Ann C. Halbower, Kelley E. Capocelli, Zhaoxing Pan, Kristen Robbins, Brian Graham, Anna Mae Diehl – 17 April 2019 – Chronic intermittent hypoxia and hedgehog (Hh) pathway dysregulation are associated with nonalcoholic fatty liver disease (NAFLD) progression. In this study, we determined the relationship between obstructive sleep apnea (OSA)/nocturnal hypoxia and Hh signaling in pediatric NAFLD.

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Arun J. Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Caldwell, Mitchell L. Shiffman, Raul Aguilar Schall, Catherine Jia, Bryan McColgan, C. Stephen Djedjos, John G. McHutchison, G. Mani Subramanian, Robert P. Myers, Zobair Younossi, Andrew J. Muir, Nezam H. Afdhal, Jaime Bosch, Zachary Goodman – 16 April 2019 – Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized.

Subscribe to